Skip to content
Wenlo
Sign in
← Markets

AbbVie Inc.

Jeffrey Ryan Stewart (EVP, CHIEF COMMERCIAL OFFICER) sells ABBV shares

4ABBVFiled Nov 12, 2026, 5:00 PM ET· Period Nov 9, 2026

AI-generated summary

Jeffrey Ryan Stewart, EVP, CHIEF COMMERCIAL OFFICER, exercised 40,619 derivative shares for $4,133,096.70, sold 40,619 shares for $11,925,738.40 at an average price of $293.60, and gifted 3,450 shares. After these transactions, the insider directly held 79,721 shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Jeffrey Ryan Stewart · EVP, CHIEF COMMERCIAL OFFICER
DateTransactionSharesPriceValueHeld afterOwnership
Nov 9, 2026M · exercise or conversion of a derivative+16,070$114.36$1,837,765.2099,241Direct
Nov 9, 2026M · exercise or conversion of a derivative+24,549$93.50$2,295,331.50123,790Direct
Nov 9, 2026S · open-market saleFootnotes F1−40,619$293.60$11,925,738.4083,171Direct
Nov 12, 2026G · gift−3,450$0.00$0.0079,721Direct
Nov 9, 2026M · exercise or conversion of a derivativeOption (Right to Buy)Footnotes F3−16,070$0.00$0.000Direct
Nov 9, 2026M · exercise or conversion of a derivativeOption (Right to Buy)Footnotes F4−24,549$0.00$0.0024,550Direct
Footnotes
  1. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  2. F2 The reporting person disclaims beneficial ownership of all securities held by his spouse.
  3. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021.
  4. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.

More ABBV filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.